Q3 2026 Globus Medical, Inc. Earnings Conference Call - GLOBUS MEDICAL INC

Explicit Guidance:

• Full-Year 2026 Revenue: Revised downward to $3.09 billion (previously $3.18–$3.22 billion), implying 5.1% growth over 2025; guidance implies a mid-single-digit decline in Q4 2026.
• Full-Year 2026 EPS (Non-GAAP): Reiterated at $4.95–$5.05 per share, representing 24.4%–26.9% growth over 2025.
• Full-Year 2026 Gross Margin: Adjusted gross profit margin expected to land between 69% and 70% (a 90–190 bps improvement over 2025), with a long-term target of mid-70s.
• Full-Year 2026 R&D Expense: Expected to be 4.5%–5.0% of net sales; a step-up in R&D spending is anticipated in coming quarters to support new product launches.
• Capital Allocation: $500 million additional share repurchase authorization added (totaling $1 billion total program as of Q3 2026); $110 million remaining under the original $500M Q2 2025 program.

Business-Segment Outlook:

• U.S. Spine: Expected to grow above market rates in 2027 driven by meaningful new product launches (Scrip, XLIF prone solution) and competitive recruiting. Delayed launches are shifted to contribute meaningfully in 2027.
• Scrip Product Line: 3D-printed patient-specific implants and rods are now available; expected to be a meaningful revenue contributor starting in 2027, leveraging surgeon excitement and reimbursement qualifications.
• Enabling Technologies (Robots/Navigation): eGPS/eHub unit deployments grew 73% YoY; expected to drive implant pull-through growth in 2027 and beyond. Transition to rental/lease models will reduce upfront 2026 revenue but increase recurring revenue streams long-term.
• Neurology (Nevro): Revenue recovery delayed until 2027. New HFX Elite IPG (with bolus therapy/MRI labeling) slated for first-half 2027 commercial launch to catalyze growth. Focus on stabilizing sales force and increasing trial volumes.
• Trauma: Expected to contribute incrementally higher to consolidated growth each year through 2027, driven by converting Level 1/2 trauma centers. No near-term M&A focus for this segment.
• International: Excluding Nevro, growth is strong (11.6% YTD); Japan remains a slower-growing region with ongoing integration disruption.
• Cranial Neurosurgery: Expansion via Synaptive acquisition aims to establish Globus as a leading player in a ~2M annual procedure market; dedicated sales team and ecosystem development planned.

Market and Competitive Outlook:

• Demand Trends: Surgeon demand and anticipation for new products (Scrip, XLIF prone) are high; "backlog" described as "anticipation" rather than order inventory.
• Pricing & Competition: Biologics pricing remains highly competitive in RFPs; focus is on increasing attachment rates within procedures. Competitive recruiting remains a key growth lever, requiring aggressive expansion of sales territories.
• Structural Changes: Transition to flexible capital acquisition (rentals/leases) for capital equipment is expected to shift Q4 2026 and 2027 revenue mix toward lower upfront sales and higher recurring service/implant revenue.
• Market Share: Strategy focuses on penetrating new call points (cranial, pain) and leveraging "connected workflow" ecosystems to gain share against established competitors.

Macro / Industry Outlook:

• Economic Conditions: Management declined to attribute Q3 slowdowns to broader market softness, attributing misses primarily to internal execution (launch delays, recruiting).
• Regulatory/Compliance: FDA warning letter regarding eGPS (July 2024) officially closed following corrective actions; no patient safety issues identified.
• FX/Tariffs: Not explicitly quantified in outlook, though constant currency guidance indicates currency impacts are being monitored.

Strategic Initiatives:

• Product Launches (2027):
  • Scrip: Full commercial scale-up expected in 2027.
  • XLIF Prone Solution & Two-Blade Retractor: Available later in Q3 2026; meaningful growth driver in 2027.
  • eIQ Suite: Next-gen pedicle fixation with AI software and robotics; expected to be a "meaningful contributor to revenue in 2027 and beyond."
  • HFX Elite (Nevro): Launch in H1 2027 to drive pain market growth.
• M&A / Acquisitions:
  • Higgs Boson (Aug 2026): Digital innovation/AI-based surgical intelligence layer; focused on improving patient outcomes from 70% to 95% via closed-loop data; not a near-term revenue contributor.
  • Synaptive Assets (Q3 2026): Acquisition via Canadian receivership to expand into cranial neurosurgery; focused on building a unified ecosystem of capital, software, and disposables.
• Organizational Restructuring:
  • Nevro: Right-sizing completed; sales force rehiring/training underway; cost control measures driving margin expansion (EBITDA margin ~19.9% in Q3).
  • IR/Corp Dev Split: Investor Relations and Corporate Development separated to allow dedicated leadership for both functions.

Risks and Headwinds to Outlook:

• Product Launch Delays: Continued production issues or timing delays for key launches could further impact 2026 revenue and push growth inflection points.
• Nevro Recovery: Risk that trial volumes and sales force productivity do not return to expected levels in 2026, delaying revenue growth in the pain franchise.
• Competitive Recruiting: Failure to accelerate territory expansion or retain newly hired competitive reps could hinder growth targets.
• R&D Spend: Anticipated increase in R&D investment in 2027 may partially offset gross margin improvements and earnings leverage.
• International Disruption: Ongoing integration challenges in Japan and other international markets could dampen growth rates.

Management Tone on the Future:

• Confidence Level: Management expresses high confidence in the long-term trajectory for 2027, describing the U.S. Spine business as positioned for "above-market" growth and the company as "healthy."
• Forward-Looking Stance: Acknowledges "bumps and air pockets" in 2026 due to execution delays but maintains focus on the "long game."
• Strategic Clarity: Reaffirms a disciplined capital allocation strategy prioritizing product development first, followed by share buybacks, with M&A viewed as tuck-in technology acquisitions rather than large transformative deals.

Miscellaneous:

• Shareholder Returns: Q3 2026 saw $143 million deployed to repurchase 1.9 million shares; share repurchases represented ~50% of YTD free cash flow.
• Non-GAAP Adjustments: Excludes one-time litigation charges from Q3 2026 SG&A in non-GAAP reporting.
• Q&A Specifics: Management declined to provide a specific revenue miss number for Q3 but attributed it to launch timing and rep recruiting pace. 2027 organic growth expectations are framed as "mid-to-high single digits" but no formal guidance was issued.